NAMS NewAmsterdam Pharma Company N.V.
USHealthcareAs of 2026-07-09 16:00
Why NAMS matters now
NewAmsterdam Pharma Company N.V. (NAMS) is a US stock in Healthcare. The latest InvestLog snapshot shows $35.92 with +0.25% on the session and $4.20B in market capitalization; recent performance reads 1-month -11.54% and YTD -14.97%.
The latest financial table shown here is Q1 2026, with revenue of $3.0M, net income of $-48.4M, and EPS of $-0.40. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -4.1%.
The latest indexable market news headline is "NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $47.00; recent insider activity includes Kooij Louise Frederika filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.43
P/S
154.54
EV/EBITDA
-14.26
DCF Value
$3.53
FCF Yield
-4.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.5%
Operating Margin
-953.6%
Net Margin
-942.8%
ROE
-29.8%
ROA
-29.0%
ROIC
-32.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.0M | $-48.4M | $-0.40 |
| Q4 2025 | $32.0K | $-74.9M | $-0.65 |
| FY 2025 | $22.5M | $-203.8M | $-1.75 |
| Q3 2025 | $348.0K | $-72.0M | $-0.61 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$49.00
Target (Median)
$47.00
Target Range
$45.00 - $55.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.08
NewAmsterdam Pharma Company N.V. functions as a clinical-phase biopharmaceutical enterprise, dedicated to enhancing treatment outcomes for patients dealing with metabolic disorders. The company's principal experimental medication, obicetrapib, represents a pioneering and targeted inhibitor that acts on the Cholesteryl Ester Transfer Protein (CETP). This compound has demonstrated in clinical studies its capacity to lower low-density lipoprotein cholesterol (LDL-C) and, concurrently, significantly elevate high-density lipoprotein cholesterol (HDL-C). Established in 2019, the company is headquartered in Naarden, the Netherlands.